Sorafenib Terminated Phase 1 / 2 Trials for Hepatocellular,Carcinoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT00828594Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
NCT01348503Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
NCT02323906Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer